Cidara Therapeutics, Inc.
General ticker "CDTX" information:
- Sector: Health Care
- Industry: Biotechnology
- Capitalization: $579.5M (TTM average)
Cidara Therapeutics, Inc. follows the US Stock Market performance with the rate: 39.2%.
Estimated limits based on current volatility of 0.6%: low 219.12$, high 220.43$
Factors to consider:
- Total employees count: 38 (-44.9%) as of 2024
- Top business risk factors: Geopolitical risks, Regulatory and compliance, Labor/talent shortage/retention, Strategic risks and growth management, Market volatility
- Current price 581.3% above estimated high
- Earnings for 9 months up through Q3 exceed our estimates
Stock Forecast*
* forecast is subjective and experimental, should not be used for any investment decisions
Long term estimates were made for the period from 2024-12-31 to 2026-12-31
- 2024-12-31 to 2025-12-31 estimated range: [10.42$, 32.37$]
- 2025-12-31 to 2026-12-31 estimated range: [5.77$, 19.28$]
Financial Metrics affecting the CDTX estimates:
- Negative: with PPE of -2.2 at the end of fiscal year the price was very high
- Negative: negative Operating income
- Negative: Operating cash flow per share per price, % of -117.96 <= 0.33
- Negative: negative Industry operating cash flow (median)
- Negative: negative Net income
- Positive: Shareholder equity ratio, % of 76.03 > 63.39
- Positive: Industry inventory ratio change (median), % of 0 <= 0
- Positive: Investing cash flow per share per price, % of -0.09 > -0.66
Short-term CDTX quotes
Long-term CDTX plot with estimates
Financial data
| YTD | 2022-12-31 | 2023-12-31 | 2024-12-31 |
|---|---|---|---|
| Operating Revenue | $64.45MM | $23.28MM | $1.27MM |
| Operating Expenses | $97.95MM | $50.34MM | $177.38MM |
| Operating Income | $-33.50MM | $-27.06MM | $-176.10MM |
| Non-Operating Income | $0.19MM | $2.00MM | $5.81MM |
| R&D Expense | $77.41MM | $36.76MM | $156.76MM |
| Income(Loss) | $-33.31MM | $-25.07MM | $-170.29MM |
| Taxes | $0.27MM | $0.01MM | $0.00MM |
| Profit(Loss)* | $-33.58MM | $-22.93MM | $-169.83MM |
| Stockholders Equity | $-14.44MM | $-8.21MM | $163.31MM |
| Inventory | $0.00MM | $6.10MM | $0.00MM |
| Assets | $47.49MM | $67.03MM | $214.80MM |
| Operating Cash Flow | $-28.47MM | $-22.43MM | $-176.53MM |
| Capital expenditure | $0.12MM | $0.51MM | $0.13MM |
| Investing Cash Flow | $-0.12MM | $-0.51MM | $-0.13MM |
| Financing Cash Flow | $-0.95MM | $25.98MM | $337.06MM |
| Earnings Per Share** | $-9.61 | $-5.25 | $-26.75 |
* Profit(Loss) attributable to entity.
** EPS are Split Adjusted, recent splits may be reflected with a delay.